ARTICLE | Finance
Blood money
Why Flagship picked red blood cells as a fundable modality
December 21, 2015 8:00 AM UTC
Flagship Ventures appears to have a thing for platform companies developing novel therapeutic modalities. The company debuted Rubius Therapeutics Inc. this month with a $25 million series A round to develop a basket of engineered red blood cells for multiple indications.
It's the third start-up with a new therapeutic modality launched this quarter, and at least the seventh among 19 companies incubated within the VC's VentureLabs group...